<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212586</url>
  </required_header>
  <id_info>
    <org_study_id>18922</org_study_id>
    <secondary_id>2017-000978-11</secondary_id>
    <nct_id>NCT03212586</nct_id>
  </id_info>
  <brief_title>BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect</brief_title>
  <official_title>Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY1902607 Including the Relative Bioavailability Between Different Pharmaceutical Formulations and the Effect of Food on the Pharmacokinetics of BAY1902607 in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-man study that will investigate the safety, tolerability and
      pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled,
      randomized, single center design. In addition the influence of food on the pharmacokinetics
      of BAY1902607 and the bioavailability between different pharmaceutical formulations will be
      investigated
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Anticipated">June 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events</measure>
    <time_frame>over 1 week</time_frame>
    <description>The frequency of adverse events collected from dosing until follow up, i.e. 1 week after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events</measure>
    <time_frame>over 1 week</time_frame>
    <description>The severity of adverse events collected from dosing until follow up, i.e. 1 week after dosing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Clinical Trials, Phase I as Topic</condition>
  <arm_group>
    <arm_group_label>Dose escalation BAY1902607</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 to 9 of BAY1902607</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose 1 to 9 of matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1902607</intervention_name>
    <description>Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)</description>
    <arm_group_label>Dose escalation BAY1902607</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)</description>
    <arm_group_label>Dose escalation Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects.

          -  Age: 18 to 45 years (inclusive) .

          -  Body mass index (BMI) : ≥18 and ≤30 kg/m².

          -  Race: White.

        Exclusion Criteria:

          -  Any findings from the medical examination (including medical history, physical
             examination, vital signs, laboratory tests and ECG) deviating from normal and deemed
             by the investigator to be of clinical relevance.

          -  Relevant diseases within the 4 weeks before the first drug administration.

          -  Febrile illness within the week before the first taste test is conducted.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical Research Services Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

